Vertex Pharmaceuticals Inc VRTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
401.08UNCH (UNCH)
Volume
36,267
Close
401.08quote price arrow up+0.92 (+0.23%)
Volume
1,027,207
52 week range
320.01 - 448.40
Loading...
  • Open401.50
  • Day High405.67
  • Day Low397.59
  • Prev Close400.16
  • 52 Week High448.40
  • 52 Week High Date01/30/24
  • 52 Week Low320.01
  • 52 Week Low Date06/01/23

Key Stats

  • Market Cap103.663B
  • Shares Out258.46M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.38
  • YTD % Change-1.43

KEY STATS

  • Open401.50
  • Day High405.67
  • Day Low397.59
  • Prev Close400.16
  • 52 Week High448.40
  • 52 Week High Date01/30/24
  • 52 Week Low320.01
  • 52 Week Low Date06/01/23
  • Market Cap103.663B
  • Shares Out258.46M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.38
  • YTD % Change-1.43

RATIOS/PROFITABILITY

  • EPS (TTM)13.89
  • P/E (TTM)28.87
  • Fwd P/E (NTM)24.12
  • EBITDA (TTM)4.013B
  • ROE (TTM)22.99%
  • Revenue (TTM)9.869B
  • Gross Margin (TTM)87.21%
  • Net Margin (TTM)36.68%
  • Debt To Equity (MRQ)2.14%

EVENTS

  • Earnings Date05/06/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Related Video

Thursday’s rapid fire: Nike, Vertex Pharmaceuticals, CarMax, Airbnb, Visa and Mastercard
VIDEO1:3101:31
Thursday’s rapid fire: Nike, Vertex Pharmaceuticals, CarMax, Airbnb, Visa and Mastercard

Profile

MORE
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage...
Jeffrey Leiden M.D., Ph.D.
Executive Chairman of the Board
Reshma Kewalramani
President, Chief Executive Officer, Director
Stuart Arbuckle
Chief Operating Officer, Executive Vice President
Charles Wagner Jr.
Chief Financial Officer, Executive Vice President
Carmen Bozic M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Address
50 Northern Avenue
Boston, MA
02210
United States

Top Peers

SYMBOLLASTCHG%CHG
ZTS
Zoetis Inc
167.07-0.16-0.10%
GILD
Gilead Sciences Inc
64.78-0.55-0.84%
HLN
Haleon PLC
8.30-0.02-0.24%
TAK
Takeda Pharmaceutical Co Ltd
13.37+0.10+0.75%
GSK
GSK plc
43.50+0.15+0.35%